PHARMA NEWS

PHARMA NEWS :- Pharmatimes

Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity June 4, 2026
Late‑breaking EULAR results highlight sustained responses through week 52
John Pinching
European approval enables measles protection with CSL’s immunoglobulin Privigen June 4, 2026
Commission authorisation expands access to passive measles prophylaxis for vulnerable patients
John Pinching
JJP Biologics reports positive interim phase 1b data for nebaprubart June 3, 2026
Early clinical activity supports expansion into broader IgA‑mediated conditions
John Pinching
Immunotherapy boost can spare more bladder cancer patients major surgery June 3, 2026
Adding durvalumab to chemoradiation helps people avoid having their bladder removed
John Pinching
Deep Science Ventures and MDC partner to accelerate brain treatments June 2, 2026
New collaboration aims to break barriers in brain‑targeted drug discovery
John Pinching
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb June 2, 2026
Aragen scales Daretabart to commercial-ready production following rapid 9‑month tech transfer
John Pinching
Spectrum of truth June 1, 2026
Accuracy is a vital metric when confirming a spectrophotometer’s suitability
John Pinching
Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen May 26, 2026
Data shows survival benefit in BRAFV600E‑mutant metastatic colorectal cancer
John Pinching
Resolution Therapeutics hails positive 4‑year MATCH data in liver cirrhosis May 26, 2026
Findings strengthen rationale for EMERALD trial of engineered macrophage therapy RTX001
John Pinching
KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy May 20, 2026
Phase 1 study to assess safety and early efficacy of KMA‑targeting car‑t in multiple myeloma
John Pinching

PHARMA NEWS :- Pharma Voice

BMS under pressure in schizophrenia; Summit/Akeso on a winning streak June 5, 2026
While the large pharma’s new drug Cobenfy has stumbled in schizophrenia, it could find new life in Alzheimer’s disease
PharmaVoice staff
GSK, Takeda and others notch key clinical wins in tough-to-treat diseases June 5, 2026
From hepatitis B to melanoma, recent study results show innovative approaches are gaining ground.
Kelly Bilodeau
House bill aims to crack down on China biotech deals June 4, 2026
A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national security.
Kristin Jensen
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target? June 4, 2026
While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.
Kelly Bilodeau
When the ISS comes down, will its drug R&D be lost in space? June 3, 2026
As NASA prepares to bring its hallmark space lab back to Earth, a host of private companies are emerging to fill the gap.
Meagan Parrish
As amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next June 2, 2026
The Alzheimer’s pipeline is growing as drug developers put more emphasis on inflammation, tau and biomarkers.
Kelly Bilodeau
AstraZeneca aims for a new blockbuster run in cardio disease June 1, 2026
With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight management and beyond, according to a company exec.
Alexandra Pecci
Can AI crack pharma’s drug repurposing goldmine? May 29, 2026
With AI now capable of analyzing decades’ worth of data, FDA is pushing pharma to leverage its “enormous, untapped value” by repurposing drugs.
Alivia Kaylor
Longevity science picks up steam in pharma May 29, 2026
Fueled by multi-billion-dollar valuations and a deeper understanding of aging biology, the field is rapidly moving past the hype and into the clinic.
Kelly Bilodeau
Vertex’s Journavx made history, but left a void in the pain space May 28, 2026
The search is still on for an opioid alternative and many companies are betting on ion channel drugs to fill the gap.
Kelly Bilodeau

Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
Late‑breaking EULAR results highlight sustained responses through week 52
European approval enables measles protection with CSL’s immunoglobulin Privigen
Commission authorisation expands access to passive measles prophylaxis for vulnerable patients
JJP Biologics reports positive interim phase 1b data for nebaprubart
Early clinical activity supports expansion into broader IgA‑mediated conditions
Immunotherapy boost can spare more bladder cancer patients major surgery
Adding durvalumab to chemoradiation helps people avoid having their bladder removed
Deep Science Ventures and MDC partner to accelerate brain treatments
New collaboration aims to break barriers in brain‑targeted drug discovery
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb
Aragen scales Daretabart to commercial-ready production following rapid 9‑month tech transfer
Spectrum of truth
Accuracy is a vital metric when confirming a spectrophotometer’s suitability
Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen
Data shows survival benefit in BRAFV600E‑mutant metastatic colorectal cancer
Resolution Therapeutics hails positive 4‑year MATCH data in liver cirrhosis
Findings strengthen rationale for EMERALD trial of engineered macrophage therapy RTX001
KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy
Phase 1 study to assess safety and early efficacy of KMA‑targeting car‑t in multiple myeloma

GMP and Quality

Non-conformances in Pharmaceutical Laboratories

Pharma VedMay 8, 2024

Pharmaceutical quality control laboratories are the guardians of public health. Through meticulous testing of raw materials, in-process materials, and finished products, they ensure the safety and efficacy of medications. However, nonconformances can arise...